Weber Shandwick wins Lipitor account

Share this article:
Pfizer named Weber Shandwick PR agency of record for Lipitor following a break with WPP. Weber Shandwick was recently appointed agency of record for the firm's statin torcetrapib/atorvastatin.

The award, first reported in PRWeek, follows a review pitting Weber Shandwick, an Interpublic Group agency, against Omnicom's Fleishman-Hillard, WPP's GCI Group and independent APCO Worldwide.

In October, Pfizer parted ways with WPP network consortium WPP Health Success, which had handled the Lipitor, Norvasc and Caduet business globally for over two years. WPP Health Success did not pitch for the Lipitor business. WPP's Feinstein Kean continues to support Caduet in the US and Burson-Marsteller handles the brand globally.

The shift comes amid a series of frantic news cycles for the world's best-selling drug and its prospective follow-on. The American Heart Association, miffed that Pfizer released data ahead of its scheduled presentation at the group's conference, cancelled the slot altogether. More importantly, the data released showed that the new drug does elevate blood pressure, however minimally. Meanwhile, Pfizer won an appeals court ruling preserving Lipitor's patent exclusivity for three more years.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...